Zydus Lifesciences, an Ahmedabad-based pharmaceutical company, has entered into a definitive agreement to acquire Assertio Holdings, a US-based company, for $166.4 million. The acquisition will be executed through Zydus Worldwide DMCC, a subsidiary of Zydus, which will purchase all outstanding shares of Assertio at $23.50 per share in cash. Assertio is known for its specialty and oncology supportive-care therapies, including the FDA-approved drug Rolvedon, which is used to prevent febrile neutropenia in adult cancer patients undergoing chemotherapy. This acquisition is seen as a strategic move by Zydus to strengthen its foothold in the US oncology market. The transaction is structured as a tender offer, followed by a merger, and is expected to close in the financial year 2026-27, pending customary closing conditions. Legal and financial advisors are in place to facilitate the transaction.